TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Psychological evaluation of fragility
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Root Caries Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Chlorid level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PUL outcome prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Occurring Within the First 66 Days of Dosing
Endpoint domain: Adverse events/effects
Primary endpoint: Blinded Independent Central Review (BICR) Assessed Radiographic Progression-Free Survival (rPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Risk of thromboembolic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Ocular Surface Staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of heart failure patients with sleep disordered breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Return of the tablet in working order
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pharmacokinetic curve AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient self-reported outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Viral Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Transfers
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Specific CTL response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Gad deposition in the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical and radiographic measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kept medical appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CD4 T-cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD8 T-cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite Rate of Death
Endpoint domain: Mortality/survival
Primary endpoint: change of stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change of defecation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change of constipation-related symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change from baseline MADRS total score at week 8
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of patients for ICU admission
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of all-caused mortality within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Screening out rate of FH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in EDSS (Expanded Disability Status Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Kurtzke Functional Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of active labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: clinical evaluations (physical exam, laboratory tests)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chlorprothixene concentration in blood serum (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State-anxiety score of the State-Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale (VAS) score for anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Microcirculatory Flow Index (MFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rates of clinical cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rates of microbiological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Craving for cannabis
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Downregulation of PLCβ activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Downregulation of phosphorylated ERK1/2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of GP knowledge on BRCA1/2 management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetics of deferasirox
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal esophageal MII-pH parameter ranges
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Mean Number of Skin Bacterial Counts From Baseline to 72 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Mean Number of Skin Bacterial Counts From Baseline to 7 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Subjects With Significantly Colonized Catheters, Defined as > or = to 15 Colony Forming Units- CFUs
Endpoint domain: Adverse events/effects
Primary endpoint: standardized gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of RSV604
Endpoint domain: Adverse events/effects
Primary endpoint: Electrocardiographs (ECGs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Reporting Grade 3 Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to mobile phone-based intervention
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Percentage of Participants Completing All Modules
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of JNJ-63549109 at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours After Dosing (AUC[0-24h]) of JNJ-63549109 at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Least Square Mean Difference of Respiratory Syncytial Virus (RSV) Ribonucleic Acid (RNA) Viral Load Area Under the Concentration-time Curve From Day 1 to 7 (AUC[1-7])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical laboratory tests (Haematology)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: clinical laboratory tests (Biochemistry)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency, type and severity of infections
Endpoint domain: Adverse events/effects
Primary endpoint: Heart Rate (vital signs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fatty acid composition of infant RBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants to Transfer to ICU After 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants That Had Short-term Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change of Serum Prealbumin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients initiating ofatumumab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with asthma controlled
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of the Pediatric Neurophysiology of Pain Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Complete Remission with Incomplete Platelet Recovery (CRp)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Complete Remission with Incomplete Recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paediatric Anesthesia Emergence Delirium (PAED) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ability of eMRI/MRSI to predict pathologically indolent cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Antibody titers for DTaP-IPV-Hep B-PRP-T vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Visual Analog pain scores (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Reproductibility of STAR-Q
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability and comprehension of STAR-Q
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of ipilimumab treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of hospitalizations related to autoimmune disease
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of participants with bleeding or thromboembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Apnoea-Hypopnoea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Oxygen Desaturation Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Sleep Apnea Quality of Life Index (SAQLI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Functional Outcomes of Sleep Questionnaire (FOSQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Bone Mineral Density (BMD) at spine and hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of glottis closure during diaphragm activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time delay in glottis opening with respect to diaphragm activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Post op Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC0-last)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Memory Attention Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Concordance of treatment with evidence-based recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Achieving paired biopsies for PD-L1 assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetic and kinematic comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Pain NRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of Escape Analgesic Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VL Suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in discomfort score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summed Pain Intensity Difference Over 0 to 12 Hours (SPID12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: score improvement on the Yale Brown Obsessive and Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in total score on 10 item Likert scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Selective Mutism Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Innate immune functions of neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximum tolerated dose (MTD) of lenvatinib mesylate
Endpoint domain: Adverse events/effects
Primary endpoint: mean operator radiation dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positron Gamma-ray emission & voxel counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintained employed rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: feasibility and safety of transendocardial injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of adults who know their HIV status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative biliary fistula occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of ultrasound in predicting operative findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Stuttering Severity Instrument (SSI-4) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 hour calibration requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBsAg seroclearance/seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Amount of Conjunctival Secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severeness of Conjunctival Bulbar Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response as assessed by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression as assessed by RECIST criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events and other symptoms as assessed by NCI CTCAE v3.0
Endpoint domain: Adverse events/effects
Primary endpoint: cerebral ictus (ischemic or haemorragic)
Endpoint domain: Mortality/survival
Primary endpoint: nonfatal acute myocardial infarction (AMI)
Endpoint domain: Mortality/survival
Primary endpoint: Pain Intensity in Primary Region of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Intensity in Overall Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma control test (ACT®) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asthma-related healthcare utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Regression of corneal neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change in urinary 2/16-hydroxyestrone ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Total Motor Abnormal Involuntary Movement Scale (AIMS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: milk iodine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary iodine concentration in the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With Anti-D and Anti-T Concentrations Above the Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patients Who Achieve 100% Reduction in Daily OCS Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients Who Achieve 100% Reduction or a Daily OCS Dose of <=5mg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chest Wall Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compartmental chest wall volumes (composite)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of vitamin D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: detection of asymptomatic venous thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant Abnormal Laboratory Results: Serum Chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Suicidal Ideation and Suicidal Behavior as Assessed by the Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Participants With Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Analgesia Nociception Index (ANI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stone Free Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Repeat procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Sitting Systolic Blood Pressure (SiSBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lipid Fraction Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of use of JAYDESS
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CR+PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical benefit defined as a decrease in HBI, fecal lactoferrin, CRP and/or ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in left anterior descending coronary flow reserve (CFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCτ of D961H
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax,ss of D961H
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With Controlled BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change From Baseline in Heart Rate at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time required to reach 0.7 MAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adjustments made to the vaporizer settings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Astigmatism measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific IgG4 responses to JJA venom during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specific IgE responses to JJA venom during treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of DE CEDM and MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma levels of metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Modified dyspnea Borg scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified Medical Research Council Dyspnea Scale (mMRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: London chest activity of Daily Living questionnaire (LCADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Conversion rate of FES negative lesions to FES positive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Change in Total Propionibacterium Acne Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of healthcare workers with appropriate knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status